Page 98 - Clinical Development News Today

Press Release Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, announced today the appointments of Michael Cox, PharmD., MHSc, BCOP as senior vice president, head of Early Development, and…

AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage

25.07.2023 - Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase 2/3 CAPELLA trial. These latest findings underscore the ... Seite 1

– Patient-Reported Outcomes From the CAPELLA Trial Align With the Demonstrated Safety and Tolerability Profile of Lenacapavir –– Analyses Show Oral Bridging Maintains Virologic Suppression When Subcutaneous Lenacapavir Doses are Missed –FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today...

TORONTO - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics, announced today a...

/PRNewswire/ - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel...

The once-daily therapeutic agent is effective for pediatric patients and pregnant women with HIV.

Investigators aimed to support extending the US FDA labeling of Xembify to include the biweekly dosing option, therefore, providing greater flexibility and convenience for patients managing their immunodeficiencies.

/PRNewswire/ -- The "Neonatal Monitoring: Technology Innovation and Growth Opportunities" report has been added to ResearchAndMarkets.coms offering. This...

/PRNewswire/ -- The "REXULTI Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.coms offering. "This "REXULTI Drug...